Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
TPC Dorlo, M Balasegaram, JH Beijnen… - Journal of …, 2012 - academic.oup.com
Miltefosine is an alkylphosphocholine drug with demonstrated activity against various
parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 …
parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 …
Recent advances and new strategies on leishmaniasis treatment
BM Roatt, JM de Oliveira Cardoso… - Applied Microbiology …, 2020 - Springer
Leishmaniasis is one of the most important tropical neglected diseases according to the
World Health Organization. Even after more than a century, we still have few drugs for the …
World Health Organization. Even after more than a century, we still have few drugs for the …
Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical …
It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …
variation among patients. They are not intended to supplant physician judgment with respect …
Treatment options for leishmaniasis
Leishmaniasis is broadly classified into three types: cutaneous, mucocutaneous and
visceral. The visceral form is most dangerous and can result in death. Although …
visceral. The visceral form is most dangerous and can result in death. Although …
Visceral leishmaniasis: recent advances in diagnostics and treatment regimens
J van Griensven, E Diro - Infectious Disease Clinics, 2019 - id.theclinics.com
Visceral leishmaniasis (VL) is a disseminated protozoan infection caused by Leishmania
donovani and Leishmania infantum. 1 Exceptionally, dermatotropic species can visceralize …
donovani and Leishmania infantum. 1 Exceptionally, dermatotropic species can visceralize …
[HTML][HTML] Leishmaniasis chemotherapy—challenges and opportunities
SL Croft, P Olliaro - Clinical microbiology and infection, 2011 - Elsevier
Although there have been significant advances in the treatment of visceral leishmaniasis
(VL), there remain challenges to ensure that treatments effective in India are also effective in …
(VL), there remain challenges to ensure that treatments effective in India are also effective in …
An update on pharmacotherapy for leishmaniasis
Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …
Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral …
The development of an effective oral therapeutics is an immediate need for the control and
elimination of visceral leishmaniasis (VL). We exemplify the preparation and optimization of …
elimination of visceral leishmaniasis (VL). We exemplify the preparation and optimization of …
Use of antimony in the treatment of leishmaniasis: current status and future directions
In the recent past the standard treatment of kala‐azar involved the use of pentavalent
antimonials Sb (V). Because of progressive rise in treatment failure to Sb (V) was limited its …
antimonials Sb (V). Because of progressive rise in treatment failure to Sb (V) was limited its …
Chemotherapy of leishmaniasis: present challenges
Cutaneous and visceral leishmaniasis are amongst the most devastating infectious diseases
of our time, affecting millions of people worldwide. The treatment of these serious diseases …
of our time, affecting millions of people worldwide. The treatment of these serious diseases …